Electrocore Stock News

electroCore, Inc. (NASDAQ:ECOR ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Nicole Jones - IR Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial

ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore'

With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short

Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Informati

electroCore, Inc. (NASDAQ:ECOR ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posn

electroCore, Inc. (NASDAQ:ECOR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posne

ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the sec

ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Go

electroCore, Inc. (NASDAQ:ECOR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner -

ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Ex

New York, USA, March 14, 2022 (GLOBE NEWSWIRE) -- Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% During the Study Period (2018-26) As per DelveInsight analysis, the Vagus Nerve Stimulators Market is witnessing a surge primarily due to the rising prevalence of neurological diseases, the increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications, technological advancements leading to the development of new products such as non-invasive Vagus Nerve Stimulation devices, and others. DelveInsight''s Vagus Nerve Stimulators Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Vagus Nerve Stimulators companies in the market. Key Takeaways from the Global Vagus Nerve Stimulators Market According to DelveInsight analysis, North America is anticipated to dominate the global Vagus Nerve Stimulators market during the forecast period.

During the last session, electroCore Inc. (NASDAQ:ECOR)’s traded shares were 0.37 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $0.55, reflecting an intraday gain of 5.64% or $0.03. The 52-week high for the ECOR share is $2.44, that puts it down -343.64 … Boom Or Bust? Where Will electroCore Inc. (NASDAQ: ECOR) Stock Go Next? Read More »

electroCore, Inc. (ECOR) CEO Daniel Goldberger on Q4 2021 Results - Earnings Call Transcript